Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues.
Eur J Clin Microbiol Infect Dis
; 20(5): 346-9, 2001 May.
Article
in En
| MEDLINE
| ID: mdl-11453597
ABSTRACT
To assess the risk factors for esophageal candidiasis (EC), a cohort study and a case-control study were conducted using 1,368 French patients who were already participating in the Delta trial (which compared different types of antiretroviral therapy in HIV-infected patients) and who had no previous history of EC. During a median follow-up period of 19 months, 87 (6%) patients developed EC. The results of the cohort study showed an increased risk of EC associated with a low baseline CD4+ cell count (P<0.0001), a high baseline plasma HIV RNA level (P < 0.0001) and prior zidovudine therapy (P = 0.02) at entry to the study. The case-control study revealed an increased risk of EC in patients with a recent low CD4+ cell count (P < 0.0002), recent antibacterial chemotherapy (P = 0.01) and oral candidiasis (P < 0.05). Cotrimoxazole prophylaxis also increased the risk of EC (P = 0.04) in the case-control study.
Search on Google
Collection:
01-internacional
Health context:
2_ODS3
Database:
MEDLINE
Main subject:
Candidiasis, Oral
/
AIDS-Related Opportunistic Infections
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur J Clin Microbiol Infect Dis
Year:
2001
Document type:
Article